Patents by Inventor Claire Bouix-Peter

Claire Bouix-Peter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF
    Publication number: 20230382906
    Abstract: Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
    Type: Application
    Filed: March 8, 2023
    Publication date: November 30, 2023
    Inventors: Gilles OUVRY, Branislav MUSICKI, Craig HARRIS, Claire BOUIX-PETER, Marie-Hélène FOUCHET, Nicolas GEORGE
  • JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF
    Publication number: 20230279003
    Abstract: Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 7, 2023
    Inventors: Gilles OUVRY, Branislav MUSICKI, Craig HARRIS, Claire BOUIX-PETER, Marie-Hélène FOUCHET, Nicolas GEORGE
  • Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))
    Patent number: 10752617
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 25, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))
    Patent number: 10618890
    Abstract: Benzimidazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 14, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • Tetrahydroquinoline sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (t))
    Patent number: 10550110
    Abstract: Tetrahydroquinoline sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (ROR?t) are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 4, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Claire Bouix-Peter, Gilles Ouvry, Etienne Thoreau
  • Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR?(T))
    Patent number: 10457637
    Abstract: Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (ROR?t) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 29, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Claire Bouix-Peter, Gilles Ouvry, Etienne Thoreau
  • INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20190202819
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR ? (T))
    Patent number: 10246440
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 2, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20190071433
    Abstract: Benzimidazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: March 7, 2019
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • TETRAHYDROQUINOLINE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20180265500
    Abstract: Tetrahydroquinoline sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (ROR?t) are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: September 20, 2018
    Inventors: Branislav MUSICKI, Claire BOUIX-PETER, Gilles OUVRY, Etienne THOREAU
  • BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20180170869
    Abstract: Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (ROR?t) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 21, 2018
    Inventors: Branislav MUSICKI, Claire BOUIX-PETER, Gilles OUVRY, Etienne THOREAU
  • Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics
    Patent number: 9981952
    Abstract: Compounds that are agonists of the MCIR receptor and that exhibit reduced toxicity relative to other compounds of the same class are described. These compounds can have the general formula (I) wherein: R1 represents a cyclopropylmethyl or a 4-hydroxybutyl group; R2 represents a hydrogen atom or a methyl group; and also the salts and enantiomers of the corresponding compounds of general formula (I). Also described, are methods for treating hypopigmentary pathologies and photosensitive dermatoses.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: May 29, 2018
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Claire Bouix-Peter
  • INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20170342062
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 30, 2017
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics
    Patent number: 9630949
    Abstract: The present invention relates to novel compounds derived from oxoazetidine corresponding to general formula (I) to the compositions containing same, to the process for preparation thereof and to the use thereof in pharmaceutical or cosmetic compositions.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 25, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Bouix-Peter, Itaru Suzuki, Nicolas Rodeville, Pascale Mauvais, Jean-Claude Pascal
  • OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS
    Publication number: 20160237065
    Abstract: Compounds that are agonists of the MCIR receptor and that exhibit reduced toxicity relative to other compounds of the same class are described. These compounds can have the general formula (I) wherein: R1 represents a cyclopropylmethyl or a 4-hydroxybutyl group; R2 represents a hydrogen atom or a methyl group; and also the salts and enantiomers of the corresponding compounds of general formula (I). Also described, are methods for treating hypopigmentary pathologies and photosensitive dermatoses.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Inventor: Claire BOUIX-PETER
  • Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics
    Patent number: 9353083
    Abstract: Methods for treating hypopigmentary pathologies and photosensitive dermatoses are described. Also described, are compounds that are agonists of the MCIR receptor and that exhibit reduced toxicity relative to other compounds of the same class. These compounds can have the general formula (I) wherein: R1 represents a cyclopropylmethyl or a 4-hydroxybutyl group; R2 represents a hydrogen atom or a methyl group; and also the salts and enantiomers of the corresponding compounds of general formula (I).
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: May 31, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Claire Bouix-Peter
  • MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS
    Publication number: 20150329522
    Abstract: The present invention relates to novel melanocortin receptor antagonist compounds corresponding to the general formula (I) below: to compositions containing them, to the process for preparing them and to their use in pharmaceutical or cosmetic compositions.
    Type: Application
    Filed: January 30, 2015
    Publication date: November 19, 2015
    Inventors: Claire BOUIX-PETER, Isabelle CARLAVAN, Catherine SOULET, Véronique PARNET, Johannes VOEGEL
  • Peroxide derivatives, their process of preparation and their use in human medicine and in cosmetics for the treatment or prevention of acne
    Patent number: 9102607
    Abstract: Compounds of the following general formula (I): are described. Also described, are processes of their preparation and their use in therapeutic applications.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: August 11, 2015
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Bouix-Peter, Jean-Claude Pascal, Nicolas Rodeville
  • Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
    Patent number: 8962846
    Abstract: Melanocortin receptor antagonist compounds, processes for preparing them and uses thereof in human medicine and cosmetics are described. Melanocortin receptor antagonist compounds corresponding to the general formula (I): compositions containing them, and processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: February 24, 2015
    Assignee: Galderma Research & Development
    Inventors: Claire Bouix-Peter, Isabelle Carlavan, Catherine Soulet, Veronique Parnet, Johannes Voegel
  • OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS
    Publication number: 20150045559
    Abstract: The present invention relates to novel compounds derived from oxoazetidine corresponding to general formula (I) to the compositions containing same, to the process for preparation thereof and to the use thereof in pharmaceutical or cosmetic compositions.
    Type: Application
    Filed: September 26, 2014
    Publication date: February 12, 2015
    Inventors: Claire BOUIX-PETER, Itaru SUZUKI, Nicolas RODEVILLE, Pascale MAUVAIS, Jean-Claude PASCAL